Labcorp Launches AI Real-World Data Platform With AWS to Speed Alzheimer’s Research

The platform is designed to help researchers, biopharmaceutical companies, payors, and clinical research organizations analyze large, de-identified healthcare datasets in minutes, a process that traditionally takes months due to fragmented data systems and manual processing.

Labcorp has launched a new AI-powered real-world data platform in collaboration with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s disease research and improve drug development efficiency.

The platform is designed to help researchers, biopharmaceutical companies, payors, and clinical research organizations analyze large, de-identified healthcare datasets in minutes, a process that traditionally takes months due to fragmented data systems and manual processing.

According to Labcorp, the system integrates diagnostic, genomic, and claims data, with plans to incorporate electronic health records and social determinants of health data. The goal is to enable faster identification of patient cohorts, disease progression patterns, and treatment outcomes across diverse populations.

The platform leverages agentic AI models along with standardized laboratory data collected across millions of patients. It is particularly focused on Alzheimer’s disease research, where over 7.2 million Americans are currently affected, and annual care costs exceed $380 billion in the United States.

Labcorp’s EVP and Chief Information and Technology Officer, Bola Oyegunwa, stated that the platform significantly reduces the time required for data preparation and allows researchers to focus more on scientific discovery rather than data engineering.

AWS highlighted that the system uses its AI infrastructure, including Amazon Bedrock for AI agents and Amazon SageMaker for advanced analytics, to enable large-scale clinical and patient data analysis.

The platform also supports clinical trial recruitment by identifying suitable de-identified patient cohorts based on inclusion and exclusion criteria. Additionally, it provides statistical modeling tools to identify unmet clinical needs across patient populations.

Labcorp said the initial validation phase of the platform is expected to conclude in spring 2026, after which it will expand to cover additional therapeutic areas such as inflammatory diseases, cardiometabolic conditions, women’s health, and oncology.

The initiative is part of Labcorp’s broader real-world data strategy aimed at improving the speed and scale of healthcare research through AI-driven analytics and privacy-preserving data connectivity.

Stay tuned for more such updates on Digital Health News